Lupin Limited has signed a licence and supply agreement with Spektus Pharma to commercialize DeslaFlex, a novel antidepressant, in Canada.

DeslaFlex is a differentiated formulation developed by Spektus using its proprietary Flexitab oral drug-delivery platform, designed to offer dosing flexibility and improved patient management in major depressive disorder.

The partnership combines Lupin’s established commercial infrastructure in Canada with Spektus’s formulation innovation capabilities, aiming to support a successful product launch and create a foundation for future specialty portfolio expansion. The agreement also strengthens Lupin’s central nervous system (CNS) pipeline with physician-focused, value-added therapies aligned with Canada’s supportive regulatory environment.

Company leadership described the collaboration as a strategic step to expand access to more personalized treatment options in depression care, while enabling Spektus to transition from development into large-scale commercialization through an experienced global partner.

Lupin is a Mumbai-headquartered global pharmaceutical company with a broad portfolio spanning branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients across more than 100 markets. Spektus Pharma focuses on developing value-added CNS therapies using proprietary drug-delivery technologies aimed at improving clinical outcomes and patient adherence.